Skip to main content

HOPA Abstracts

Impact of Drug Repository Program in a Rural Oncology Clinic
Abstract #PM02
Read More
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
Abstract #PM01
Read More
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
Abstract #CT14
Read More
Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death
Abstract #CT13
Read More
The Incidence of Arterial and Venous Thromboembolism in Patients with Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Treated with Ponatinib
Abstract #CT12
Read More
Welcome to the First Annual Issue of HOPA Abstracts, 2021
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Read More
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Abstract #CT10
Read More
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
Abstract #CT09
Read More
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
Abstract #CT08
Read More
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
Abstract #CT07
Read More
Page 11 of 12
Results 101 - 110 of 119